Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 31, Issue 2, Pages 264-274
Publisher
Springer Nature
Online
2017-10-06
DOI
10.1038/modpathol.2017.125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overexpression of KH-type splicing regulatory protein regulates proliferation, migration, and implantation ability of osteosarcoma
- (2016) Dumnoensun Pruksakorn et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2–p53 signaling
- (2016) Chuhai Xie et al. OncoTargets and Therapy
- HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
- (2016) Elizabeth E. Hull et al. Biomed Research International
- Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma
- (2015) James S Wilmott et al. MODERN PATHOLOGY
- Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma
- (2015) Diana Yu et al. Scientific Reports
- Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors
- (2014) M. Bots et al. BLOOD
- Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer
- (2014) Anne Benard et al. HISTOPATHOLOGY
- Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
- (2014) Jinwon Seo et al. Journal of Breast Cancer
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
- (2013) Krithi Rao-Bindal et al. CURRENT CANCER DRUG TARGETS
- The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells
- (2013) Shiguo Zhu et al. PHARMACEUTICAL RESEARCH
- Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model
- (2013) C. Blattmann et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation
- (2012) Jürgen Sonnemann et al. CANCER BIOLOGY & THERAPY
- Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines
- (2012) Venugopal Thayanithy et al. PLoS One
- MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts
- (2012) K Rao-Bindal et al. Cell Death & Disease
- Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases
- (2011) Nadezhda V. Koshkina et al. CANCER
- Histone deacetylases in skeletal development and bone mass maintenance
- (2010) Meghan E. McGee-Lawrence et al. GENE
- Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity
- (2010) Yamanegi ONCOLOGY REPORTS
- High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo
- (2009) Annika Lehmann et al. BMC CANCER
- Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
- (2008) Florian R Fritzsche et al. BMC CANCER
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started